Coherus BioSciences (CHRS) Tops Q4 EPS by 20c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.60), $0.20 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $45.35 million versus the consensus estimate of $48.41 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- AXIL Brands (AXIL) Tops Q4 EPS by 4c
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
